apomorphine (Apokyn®) 

INITIATION DOSE IS OFFICE ADMINISTERED: SUBCUTANEOUS INJECTION

Indication(s) for Prior Authorization:

  • Parkinson’s Disease, treatment of hypomobility

Patients must meet all the following criteria for the indication above:

  • Adjunctive treatment for patients with advanced Parkinson’s Disease experiencing acute hypomobility secondary to end-of-dose wearing off  episodes or unpredictable off  episodes
  • Prescribed or recommended by a neurologist
  • Must be on concurrent therapy with: carbidopa-levodopa (Sinemet ®) at the maximum tolerated dose and a second agent such as a MAO-B inhibitor, Dopamine Agonist or COMT inhibitor
  • Concurrent therapy with trimethobenzamide (Tigan) – 3 days prior to initiation and continued for at least 2 months after apomorphine
  • Contraindicated in patients who are currently taking 5HT3 antagonists

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Any Indication not listed above

Dosing:

  • Up to 0.6 ml (6 mg) subcutaneously

 

Last review date: December 1, 2014

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar